Welcome to Cizzle Biotech Limited, a spin out company from the University of York, founded around the work of Dr Dawn Coverley and colleagues and is led by David Browning, CEO. Product development is focused on the CIZ1 gene and its potential as a diagnostic biomarker and therapeutic target for cancer.

The Company is supported by funds primarily from the White Rose Seed Fund and Yorkshire Cancer Research.

Cizzle’s mission is the creation of value through the development of world leading science into innovative diagnostic products in partnership with the biotech and pharma industries.  Cizzle’s lead program is focused on a specific variant of Ciz1 as a biomarker for the early detection and management of lung cancer.

Cizzle Biotech Limited
Heslington Hall, Heslington, York, North Yorkshire, Y010 5DD
UK company 5249093